Skip to content

Clinical Outcomes of Bilateral Clareon Vivity in Post-Refractive Patients

Clinical Outcomes of Bilateral Clareon Vivity in Post-Refractive Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06924944
Enrollment
35
Registered
2025-04-13
Start date
2025-01-20
Completion date
2026-04-30
Last updated
2025-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract Surgery, Correction Vision Surgery

Brief summary

Millions of people have undergone laser vision correction surgery and are motivated to continue with spectacle independence as they develop presbyopia (gradual loss of your eyes' ability to focus on nearby objects)and cataract. However, having a history of refractive surgery, poses challenges in the selection of the IOLs and can lead to visual outcomes that are unpredictable. Data from an international registry and single prospective study show that Vivity IOL provided effective distance, intermediate and near vision in eyes with previous LASIK with minimal effects on day vision associated with the surgery. The purpose of this study is to evaluate the clinical outcomes of post-myopic refractive surgery patients implanted with the Clareon Vivity/Vivity Toric lenses

Interventions

PROCEDUREcataract surgery

cataract surgery treated with bilateral Clareon Vivity toric and non-toric IOL

Sponsors

Utah Eye Centers
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* o Bilateral age-related visually significant cataracts in otherwise healthy eyes, undergoing uncomplicated bilateral sequential Clareon Vivity IOLs * Prior history of uncomplicated post-refractive myopic surgery (LASIK/PRK) with up to 1 enhancement treatment * Potential acuity measured post-operatively 20/25 or better in both eyes * Patients with regular astigmatism that can be managed with T3 toric lens or arcuate incision

Exclusion criteria

* o Ocular or systemic comorbidities that may alter or reduce visual acuity and contrast sensitivity such as severe dry eye/ocular surface disease, glaucoma, macular degeneration, retinopathy, neuro-ophthalmic diseases, etc. * Prior ocular surgeries other than uncomplicated corneal refractive surgery and excluding RK * Patients with irregular astigmatism/topography (to rule out signs of potential ectasia), corneal dystrophies, and pupil abnormalities * Total HOA cutoff of ≤0.5, coma ≤0.3 * RLE patients

Design outcomes

Primary

MeasureTime frame
Binocular photopic uncorrected distance VA (at 3 months)at 3 months

Secondary

MeasureTime frame
• Binocular photopic uncorrected VA at intermediate (66cm) and near (40cm)at 3 months

Other

MeasureTime frame
Monocular and binocular best distance corrected distance, intermediate, and near VAat 3 months
Monocular uncorrected distance, intermediate, and near VAat 3 months
Mean difference of MRSE between dominant and non-dominant eyeat 3 months
Binocular photopic low contrast distance corrected VAat 3 months
Visual disturbances via QUVID questionnaireat 3 months
Potential association between HOA (SA and coma) and monocular DCVAsat 3 months
% of eyes with absolute prediction error less than or equal to 0.5Dat 3 months
Mean refractive spherical equivalent (MRSE) for dominant and non-dominant eyeat 3 months

Countries

United States

Contacts

Primary ContactRachel Buchanan
rbuchanan@utaheyecenters.com8014099873

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026